Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy versus androgen deprivation therapy for androgen receptor-positive recurrent/metastatic salivary gland cancer
NL-OMON54823Phase 2Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bicalutamide, triptorelin, cisplatin, carboplatin, doxorubicin and 1 more in salivary gland cancer (SGC), salivary duct carcinoma (SDC) and Salivary gland adenocarcinoma (SGAC) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Progression-Free Survival and Best Overall Response. Started Sep 2015; status: recruiting.
02
Drugs
bicalutamidetriptorelincisplatincarboplatindoxorubicin
03
Conditions
salivary gland cancer (SGC)salivary duct carcinoma (SDC)Salivary gland adenocarcinoma (SGAC)
Beyond the preview
Go deeper on NL-OMON54823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54823.